We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ultra-Rapid AST System Provides Critical Results for Sepsis Patients

By LabMedica International staff writers
Posted on 27 Dec 2024
Print article
Image: The QuickMIC system (Photo courtesy of Gradientech)
Image: The QuickMIC system (Photo courtesy of Gradientech)

Sepsis is a critical condition and one of the leading causes of death in hospitals. Millions of adults are diagnosed with sepsis each year, and it is also a primary reason for hospital readmissions. Hospital staff are urged to start treatment for life-threatening sepsis within one hour of diagnosis, often referred to as the 'golden hour.' Now, an ultra-rapid antimicrobial susceptibility testing (AST) system can support the timely and effective management of sepsis, enabling clinicians to make faster decisions regarding antibiotic treatments.

The QuickMIC ultra-rapid AST system, developed by Gradientech AB (Uppsala, Sweden), is designed to provide critical results for sepsis patients. This instrument can analyze a single positive blood culture sample per run, delivering precise minimum inhibitory concentration (MIC) values within 2–4 hours directly from positive blood cultures. The system employs unique technology based on a continuous linear antibiotic gradient, offering greater resolution, precision, and accuracy compared to methods that rely on discrete antibiotic concentrations. Microcolonies of bacteria exposed to this gradient are monitored in real-time using live imaging. The QuickMIC Analyst software then examines the growth patterns along the antibiotic gradient to determine accurate MIC values.

QuickMIC cassettes test each blood culture sample against a panel of multiple antibiotics, with each pre-filled cassette containing twelve antibiotics specifically designed for common sepsis-causing bacteria. The gram-negative antibiotic panel targets pathogens such as E. coli, Klebsiella spp., P. aeruginosa, E. cloacae, A. baumannii, Proteus spp., Citrobacter spp., and S. marcescens. Laboratories can use QuickMIC in conjunction with their preferred rapid identification methods to provide quicker results to clinical teams. Up to twelve QuickMIC instruments can be stacked together, allowing labs to increase testing capacity while saving valuable bench space. QuickMIC and its gram-negative panel are CE-marked and commercially available in Europe, although they are not yet available for sale in the United States.

Related Links:
Gradientech AB

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.